Conexeu Labs
Innovation at the Heart of Regeneration
A patented collagen tissue scaffold platform technology with unprecedented potential.
A patented collagen based platform:
CXU™ Tissue Engineering Paltform
“Conexeu Labs is our innovation hub driving the science behind our patented collagen based platform. Discover how we’re pushing the boundaries of what’s possible in tissue engineering.”
Conexeu Mission
The Time Has Arrived
We are ushering in an era where collagen extracellular matrix (ECM) scaffolds are accessible to all; reshaping the potential of regenerative tissue engineering.
As demand grows for safe, effective regenerative solutions in the aesthetic and tissue repair, Conexeu’s investigative ECM innovation is seeking to address critical gaps in patient care and true tissue regeneration.
History
10+ Years of Research
Built on over a decade of R&D into collagen’s biological activity, Conexeu’s proprietary formulations are being developed to potentially support faster and more complete tissue repair.
Our collagen-based scaffold platform is under investigation for multiple high-value therapeutic and aesthetic applications, representing a potential leap forward in regenerative medicine.
Adaptable Applications
Aesthetics, wound care, and major reconstructive surgeries — all under one platform.
Cost-Effective
Simple composition and low-cost materials.
Patents
COLLAGEN IP
-
Secured in the USA, Japan, EU, Australia, and pending in Canada.
-
Conexeu’s patented extracellular matrix (ECM) technology — a collagen-derived, biomimetic platform — is being developed as a potential advance in regenerative medicine and tissue engineering, supported by over a decade of research at the University of British Columbia.
CXU™–Patented Technology Platform
Conexeu’s extracellular matrix (ECM) technology, a collagen-derived formulation, is being developed as a regenerative platform designed to support natural human tissue structure and function. By leveraging a sophisticated extracellular matrix composition, it seeks to provide enhanced biocompatibility.
Biologic Advantages
Preclinical data: suggest faster wound closure, rapid integration, and early vascularization may result in fewer complications.
Potentially reduced inflammation: a shortened inflammatory phase may expedite healing and facilitate inflammatory cells.
Low-scar healing: a non-fibrotic collagen matrix may foster organized cell growth, helping to minimize scarring.
Improved cell viability (preclinical): post-healing, cells have been observed to thrive in the CXU scaffold.
CXU is an investigational device. Limited by federal (U.S.) law to investigational use. Safety and effectiveness have not been established.
CXU™ Applications
Partial mastectomy, burns, and acute wounds.
Small-volume dermal repair (face and hands).
Large-volume augmentation (non-surgical buttocks and breast enhancements).
Precision tissue engineering applications (breast implants).
Partial mastectomy.
Our Products
Other Product Pipeline
Medical Aesthetics
Patented Collagen Scaffold Technology
Redefining aesthetic medicine through regenerative innovation that spans dermal fillers to large-volume enhancements.
Tissue Reconstruction
10 Minute Tissue
Enhancing the body’s natural ability to restore and repair skin, tissues, and structures using a patented collagen scaffold.
Publications
Advancing Skin Regeneration Science
About Us
Our Science Team
Led by a multidisciplinary group of regenerative medicine experts, Conexeu merges biomaterials engineering and clinical insight to continually advance tissue regeneration technologies.
Summary
Conexeu Labs is our innovation hub driving the science behind our patented collagen-based platform. By leveraging biomimetic ECM structures to guide natural cell growth, we achieve superior tissue integration with minimized inflammation or fibrosis.
Discover how we’re pushing the boundaries of what’s possible in tissue engineering.
Investors
A Transformational Opportunity in Regenerative Medicine
Growing Market Demand.
The global shift toward safer, natural aesthetic and reconstructive solutions continues to expand.
Provisional Science.
Supported by preclinical, peer-reviewed data, Conexeu’s patented collagen approach is being investigated for applications ranging from facial rejuvenation to large-volume body contouring.
Seasoned Leadership.
World-renowned aesthetic surgeon, tissue-engineering PhDs, former CEOs/CMOs of global aesthetics leaders, and medical device veterans with proven FDA-clearance track records.
“Join Us in Shaping the Future of Regenerative Medicine”
At Conexeu, we’re not just introducing another facial filler; we’re igniting a paradigm shift in how medicine approaches tissue restoration. From investors seeking high-growth opportunities to clinicians pursuing safer and more effective therapies—everyone benefits from a future driven by true regeneration.
Join our newsletter to track our innovations and breakthroughs.
"*" indicates required fields